Fennec Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $12,462 | $9,652 | $8,751 | $7,925 |
Gross Profit | 11,802 | 8,685 | 8,378 | 7,256 |
EBITDA | -1 | -2,533 | -782 | -909 |
EBIT | -52 | -2,558 | -808 | -934 |
Net Income | -638 | -3,152 | -1,165 | -1,985 |
Net Change In Cash | 12,462 | 9,652 | 8,751 | 7,925 |
Free Cash Flow | 1,493 | -3,686 | -4,318 | -1,474 |
Cash | 21,925 | 18,705 | 22,675 | 26,634 |
Basic Shares | 27,889 | 27,664 | 27,578 | 27,460 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $47,538 | $21,252 | $1,474 | $170 |
Gross Profit | 44,354 | 19,993 | 1,391 | 0 |
EBITDA | 4,798 | -12,364 | -21,692 | -17,068 |
EBIT | 3,998 | -12,651 | -22,736 | -17,346 |
Net Income | -436 | -16,045 | -22,774 | -17,193 |
Net Change In Cash | 47,538 | 21,252 | 1,474 | 170 |
Cost of Revenue | -9,244 | |||
Free Cash Flow | 26,980 | -17,143 | -18,058 | -14,222 |
Cash | 26,634 | 13,269 | 23,774 | 21,100 |
Basic Shares | 27,294 | 26,574 | 26,275 | 26,006 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$0.02 |
2025-06-30 | -$0.11 |
2025-03-31 | -$0.04 |
2024-12-31 | -$0.06 |
